Section Arrow
DSGN.NASDAQ
- Design Therapeutics
Quotes are at least 15-min delayed:2026/02/19 05:15 EST
Pre Market
Last
 --
-- (--)
Bid
4.02
Ask
15.94
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 10.03
-0.09 (-0.89%)
Day High 
10.4 
Prev. Close
10.12 
1-M High
10.97 
Volume 
147.08K 
Bid
4.02
Ask
15.94
Day Low
10 
Open
10.14 
1-M Low
9.06 
Market Cap 
576.47M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 10.18 
20-SMA 10.2 
50-SMA 9.74 
52-W High 10.97 
52-W Low 2.6 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.19/-1.23
Enterprise Value
578.01M
Balance Sheet
Book Value Per Share
3.51
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.178-0.007-3.78%-- 
Pre Market 0.1804 +0.0024 +1.35%
IBRXImmunityBio8.54+2.52+41.86%-- 
Pre Market 8.48 -0.06 -0.70%
CDIOCardio Diagnostics Holdings Inc.2.13+0.94+78.99%-- 
Pre Market 1.94 -0.19 -8.92%
RXRXRecursion Pharmaceuticals3.53+0.07+2.02%-- 
Pre Market 3.43 -0.1 -2.83%
GERNGeron Corp1.94+0.14+7.78%-- 
Pre Market 1.95 +0.01 +0.52%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.